← Back to Screener
Curanex Pharmaceuticals Inc Common Stock (CURX)
Price$0.48
Favorite Metrics
Price vs S&P 500 (26W)-44.13%
Price vs S&P 500 (4W)-11.02%
Market Capitalization$12.79M
All Metrics
Book Value / Share (Quarterly)$0.40
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.37
Price vs S&P 500 (YTD)32.12%
EPS (TTM)$-0.15
10-Day Avg Trading Volume0.12M
EPS Excl Extra (TTM)$-0.15
EPS (Annual)$-0.17
ROI (Annual)-37.66%
Gross Margin (Annual)17.04%
Cash / Share (Quarterly)$0.18
ROA (Last FY)-36.49%
EBITD / Share (TTM)$-0.15
Cash Flow / Share (Annual)$-0.37
P/B Ratio1.14x
P/B Ratio (Quarterly)0.84x
Net Interest Coverage (TTM)-493.74x
ROA (TTM)-61.16%
EPS Incl Extra (Annual)$-0.17
Current Ratio (Annual)81.93x
Quick Ratio (Quarterly)36.29x
3-Month Avg Trading Volume3.05M
P/S Ratio (Annual)492.02x
Asset Turnover (Annual)2.54x
52-Week High$9.18
EPS Excl Extra (Annual)$-0.17
26-Week Price Return-35.39%
Quick Ratio (Annual)36.29x
13-Week Price Return25.98%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)81.93x
Enterprise Value$7.819
Pretax Margin (Annual)-77.81%
Cash / Share (Annual)$0.18
3-Month Return Std Dev124.20%
ROE (Last FY)-37.66%
EPS Basic Excl Extra (Annual)$-0.17
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.15
ROI (TTM)-63.10%
Revenue / Share (Annual)$0.00
Year-to-Date Return36.25%
5-Day Price Return-5.59%
EPS Normalized (Annual)$-0.17
Net Profit Margin (Annual)-77.81%
Month-to-Date Return-11.74%
EBITD / Share (Annual)$-0.17
Operating Margin (Annual)-77.81%
LT Debt / Equity (Quarterly)1.31x
EPS Basic Excl Extra (TTM)$-0.15
P/B Ratio (Annual)0.84x
Book Value / Share (Annual)$0.40
Price vs S&P 500 (13W)23.11%
Beta0.56x
P/FCF (Annual)3830.10x
Revenue / Share (TTM)$0.00
ROE (TTM)-64.55%
52-Week Low$0.26
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
CURXCuranex Pharmaceuticals Inc Common Stock | — | — | — | — | $0.48 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Curanex Pharmaceuticals develops botanical-based drugs targeting unmet medical needs in inflammatory diseases. Its lead compound, Phyto-N, is in preclinical development for six indications including ulcerative colitis, atopic dermatitis, type 2 diabetes, and NAFLD.